Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

In MS, serious adverse effects are more common in rituximab versus ocrelizumab

Key clinical point: Rituximab and ocrelizumab treatments for multiple sclerosis are linked to serious adverse events, including infections and death.

Major finding: Among all adverse events, serious AEs were more common for rituximab versus ocrelizumab (64.8% vs. 56.3%, respectively; P < .001), as were AEs linked to death (5.7% vs. 2.1%, respectively; P < .001).

Study details: A retrospective analysis of postmarketing AEs reported from patients who took the drugs to treat multiple sclerosis.

Disclosures: No study funding was reported. The corresponding author reported various disclosures.


Gonzalez Caldito N et al. Mult Scler J. 2020 Aug 21. doi: 10.1177/1352458520949986.